Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GlaxoSmithKline

Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate

Regeneron Pharmaceuticals

Sanofi and Regeneron reported a phase 3 failure with their rheumatoid arthritis treatment and severely affected COVID-19 patients.

Kevzara Fails COVID-19 Patients for the Last Time

Sanofi's (SNY) phase III study evaluating Kevzara in severely or critically ill patients hospitalized with COVID-19 fails to meet primary endpoint and key secondary endpoint.

Sanofi's Kevzara Fails as a Potential COVID-19 Treatment

AstraZeneca

AstraZeneca has started Phase 3 tests of its Covid vaccine in the U.S., but Sanofi and Regeneron said a Phase 3 test of their drug Kevzara to treat seriously ill Covid-19 patients failed.

Covid Roundup: AstraZeneca U.S. Phase 3 Vaccine Trials Start; Sanofi Drug Fails Test

Shares of Sanofi SNY, +0.75% SAN, +0.54% were up 0.9% in premarket trading on Tuesday after the drugmaker said that the rheumatoid arthritis drug Kevzara failed a Phase 3 clinical trial testing the therapy as a treatment for severely ill COVID-19 patients.

Sanofi, Regeneron: Kevzara fails in late-stage COVID-19 trial

Sanofi SA (NASDAQ: SNY) announced Tuesday that its rheumatoid arthritis drug Kevzara, developed in partnership with Regeneron Pharmaceuticals Inc.

Sanofi, Regeneron Rheumatoid Arthritis Drug Proves Ineffective Against COVID-19

PARIS  – September 1, 2020 – Sanofi today announced that the global Phase 3 trial investigating intravenously administered Kevzara® (sarilumab) at a dose of 200 mg or 400 mg[a]  in severely or critically ill[b]  patients hospitalized with COVID-19 did not meet its primary endpoint and key secondary endpoint[c] when Kevzara was compared to placebo added to usual hospital care. The 420-patient randomized trial was conducted outside the U.S. in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia and Spain (86 in placebo, 161 in 200 mg, and 173 in 400 mg arms).

Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.

BioNTech SE

Heat Biologics

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

Pfizer

Vaxart

COVID-19 vaccine stocks have gotten slammed this month.

Has The COVID-19 Vaccine Stock Bubble Burst?

Sanofi's confidence in its coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to start clinical trials, its chief executive told Reuters.

Sanofi more confident about its coronavirus vaccines

Exclusive: Sanofi more confident about its coronavirus vaccines

Principia Biopharma Inc

Sanofi to commence tender offer for acquisition of Principia Biopharma Inc.

These rough and tumble coronavirus stocks could help fund your retirement.

Got $1,000? These Dirt-Cheap Stocks Are Practically Free

Sorrento Therapeutics Inc

These are the top stocks to buy based on the 2020 U.S. presidential election, with new stock picks updated daily from the sharpest investing minds in the business.

Investing for the Election: 6 Vaccine Stocks to Buy for Operation Warp Speed

Even a vaccine that's 50% effective with some side effects would be a game changer. The Trump Administration is throwing billions into that hope and investors are seeing big profits.

6 Hot Coronavirus Stocks Moving At “Warp Speed”

AbbVie

Carlisle Companies

General Dynamics

Altria

SEI Investments

If You Like Attractively Valued Blue-Chips, You'll Love These 7 Dividend Growth Stocks

SNY stock is no longer a sleepy passive investment. Under a new CEO, Sanofi is less reliant on diabetes and heart drugs and looking to buy pre-market cancer blockbusters.

Once Slow, Stable Sanofi Stock is Now Pharma’s Most-Talked About Name

New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Principia Biopharma Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Principia Biopharma Inc. to Sanofi

This isn't the pharmaceutical giant's only recent ride at the acquisition rodeo.

Sanofi Acquiring Principia Biopharma for $3.7 Billion

CVS Health

Flu season is nearly upon us. Here’s how you can get a flu shot without worrying about going into the doctor’s office.

Sanofi and CVS are building COVID-safe flu vaccination stations

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Principia Biopharma Inc.

PRINCIPIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRNB and Encourages Investors to Contact the Firm

TOKYO--(BUSINESS WIRE)--Financial executives at Oita Chuo Pacific Management have commented on Sanofi agreeing to acquire U.S. Principia Biopharma for $3.4 billion.

Oita Chuo Pacific Management Comments on Sanofi as They Agree to Acquire U.S. Biotech Firm Principia Biopharma

Principia Biopharma Inc. (NASDAQ: PRNB) shares jumped to start out the week after it was announced that it would be acquired by Sanofi (NASDAQ: SNY).

What Sanofi Is Adding to Its Portfolio With This New Acquisition

Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.

Sanofi to Buy Immunology Firm Principia Biopharma for $3.7B

Sanofi is expanding efforts to combat MS and other autoimmune diseases by announcing a $3.68 billion acquisition of partner Principia Biopharma.
The post Sanofi To Acquire Partner Principia Biopharma, Expand MS Treatment Efforts appeared first on Investor's Business Daily.

Sanofi To Acquire Partner Principia Biopharma, Expand MS Treatment Efforts

Sanofi S.A. (EPA: SAN) expressed plans of acquiring Principia Biopharma Inc.

News for Sanofi Stock (SNY)